New Data for Precision Biologics, Inc. PB-223 ADC against novel tumor-specific target on human cancers revealed at SITC 2026

The Quick Take
BETHESDA, Md., Nov. 6, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD announces presentation of new data describing in-vivo efficacy of its novel tumor-specific antibody-drug-conjugate PB-223 ADC. Recent tumor killing data showing specific non-toxic anti-tumor...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
IMAGECARE TEAMSTERS IN NEW JERSEY AUTHORIZE STRIKE
Health Care Workers Prepare to Hit Picket Line to Win First Union Contract WAYNE, N.J., Nov. 6, 2026 /PRNewswire/ -- Members of Teamsters Local 125 at…
Business
High Performance Liquid Chromatography Market worth $12.2 billion by 2031 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., Nov. 6, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the High-Performance Liquid Chromatography (HPLC) Market is projected to…
Local
October jobs report strengthens case for December rate hike
Payrolls rose by 165,000, U-6 underemployment increased to 7.9%, and August and September gains were revised higher
Business
In HelloNation, Senior Living Expert Melinda Dally Explains Choosing Between Assisted Living and Memory Care in Monroe
The article compares care options to help families understand differences in support, safety, and daily routines. MONROE, Ga., Nov. 6, 2026 /PRNewswire/ -- How…
